Literature DB >> 22878150

Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non-small-cell lung cancer.

Takeshi Hanagiri1, Yoshiki Shigematsu, Koji Kuroda, Tetsuro Baba, Hironobu Shiota, Yoshinobu Ichiki, Yoshika Nagata, Manabu Yasuda, Hidetaka Uramoto, Tomoko So, Mitsuhiro Takenoyama, Fumihiro Tanaka.   

Abstract

BACKGROUND: The purpose of the present study was to clarify the prognostic significance of human leukocyte antigen (HLA) class I expression in patients with non-small-cell lung cancer who underwent complete surgical resection. PATIENTS AND METHODS: The expression of HLA class I molecules was evaluated in 403 resected NSCLC specimens using immunohistochemistry. The results were scored as the percentage of stained tumor cells and were categorized into three groups: 0%-24% (decreased), 25%-79% (heterogeneous), and 80% or more (normal).
RESULTS: The expression of HLA class I was evaluated in 124 tumors in the normal expression group, 181 tumors in the heterogeneous expression group, and 98 tumors in the decreased expression group. The 5-year survival rate of all patients after surgery according to the HLA class I expression in the normal, heterogeneous, and decreased groups was 76.6%, 65.9%, and 76.1%, respectively. The prognosis was significantly better in the normal expression group than in the heterogeneous group. Normal HLA class I expression also correlated with favorable survival in patients with stage I disease.
CONCLUSIONS: The normal expression of HLA class I was associated with a favorable prognosis compared with the heterogeneous expression group, but no significant difference was observed between the normal expression and decreased expression groups.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22878150     DOI: 10.1016/j.jss.2012.07.029

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  7 in total

Review 1.  Going back to class I: MHC and immunotherapies for childhood cancer.

Authors:  Kellie B Haworth; Jennifer L Leddon; Chun-Yu Chen; Edwin M Horwitz; Crystal L Mackall; Timothy P Cripe
Journal:  Pediatr Blood Cancer       Date:  2014-12-18       Impact factor: 3.167

2.  Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients.

Authors:  Tetsuro Baba; Hironobu Shiota; Koji Kuroda; Yoshiki Shigematsu; Yoshinobu Ichiki; Hidetaka Uramoto; Takeshi Hanagiri; Fumihiro Tanaka
Journal:  Int J Clin Oncol       Date:  2012-11-03       Impact factor: 3.402

3.  An analysis of the immunological tumor microenvironment of primary tumors and regional lymph nodes in squamous cell lung cancer.

Authors:  Yoshinobu Ichiki; Mari Ueno; Shinya Yanagi; Yoshiro Kanasaki; Hidenori Goto; Takashi Fukuyama; Shuji Mikami; Kozo Nakanishi; Tsuyoshi Ishida
Journal:  Transl Lung Cancer Res       Date:  2021-08

Review 4.  Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response.

Authors:  Brandie C Taylor; Justin M Balko
Journal:  Front Immunol       Date:  2022-02-28       Impact factor: 7.561

5.  The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.

Authors:  Mehrdad Talebian Yazdi; Sander van Riet; Annemarie van Schadewijk; Marta Fiocco; Thorbald van Hall; Christian Taube; Pieter S Hiemstra; Sjoerd H van der Burg
Journal:  Oncotarget       Date:  2016-01-19

6.  The role of Human leukocyte antigen class I on patient survival in Gastrointestinal cancers: a systematic review and meta- analysis.

Authors:  Hadis Najafimehr; Nastaran Hajizadeh; Ehsan Nazemalhosseini-Mojarad; Mohamad Amin Pourhoseingholi; Meghdad Abdollahpour-Alitappeh; Sara Ashtari; Mohammad Reza Zali
Journal:  Sci Rep       Date:  2020-01-20       Impact factor: 4.379

7.  Relationship between Kita-Kyushu Lung Cancer antigen-1 expression and prognosis of cases with lung squamous cell carcinoma.

Authors:  Yoshinobu Ichiki; Takashi Fukuyama; Haruki Ohmiya; Mari Ueno; Shinya Yanagi; Yoshiro Kanasaki; Hidenori Goto; Shuji Mikami; Hitoshi Yamazaki; Kozo Nakanishi; Tsuyoshi Ishida
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.